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Abstract
Background: The relationship between inducible nitric oxide synthatase activity and disease severity in
leptospirosis is unclear. Nitric oxide is converted to nitrites and nitrates, thus nitrite and nitrate levels (NOx) in serum
are considered surrogate markers for nitric oxide. NOx are excreted through the kidneys, and elimination is
diminished in renal impairment. We assessed the correlation of NOx with disease severity in patients with
leptospirosis, compared with healthy controls and non-leptospirosis fever patients.
Methods: All patients admitted over a two-month period to the National Hospital, Colombo, Sri Lanka with a
clinical picture suggestive of leptospirosis were included. Leptospirosis was confirmed by the microscopic
agglutination test (titre≥400). Severe leptospirosis was defined by the presence of two or more of the following
criteria: jaundice (bilirubin> 51.3 μmol/l), oliguria (urine output < 400 ml/day), serum creatinine> 133 μmol/l or
blood urea > 25.5 mmol/l, or the presence of organ dysfunction. Non-leptospirosis fever patients and healthy
volunteers were used as control groups. NOx levels were measured using a modified Griess reaction.
Results: Forty patients were confirmed as having leptospirosis and 26 of them had severe disease. NOx levels were
significantly higher in confirmed leptospirosis patients compared to healthy controls, MAT equivocal patients and
non-leptospirosis fever patients (p<0.001). NOx concentrations were also significantly higher in patients with severe
compared to mild leptospirosis (p<0.001). Once NOx levels were corrected for renal function, by using the ratio
NOx/creatinine, NOx levels were actually significantly lower in patients with severe disease compared to other
patients, and values were similar to those of healthy controls.
Conclusions: We postulate that high NOx levels may be protective against severe leptospirosis, and that finding
low NOx levels (when corrected for renal function) in patients with leptospirosis may predict the development of
severe disease and organ dysfunction.
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Background
Leptospirosis is a zoonotic illness that has a high mor-
bidity and mortality in the tropics [1]. It is caused by a
spirochaete of the genus Leptospira, which is now found
to have at least nine pathogenic species and over 250
serovars. The global burden of leptospirosis is difficult to
quantify due to under-reporting and difficulties in
establishing a serological diagnosis. However, it is esti-
mated that in endemic areas (localized geographical
areas in Central America, Indian subcontinent, Oceania,
and the Caribbean), the incidence of leptospirosis can be
as high as 25 clinical infections per 100,000 of popula-
tion per year (in contrast to 1 per 100,000 per year in
non-endemic areas) [2].
The majority of infections are asymptomatic or may
pass off as a flu like illness. However, severe leptospirosis
can be fatal. Severe leptospirosis is associated with adult
respiratory distress syndrome (ARDS), pulmonary haem-
orrhage, acute kidney injury, liver impairment, and
multi-organ dysfunction syndrome (MODS) [3,4]. The
case fatality in severe leptospirosis (Weil’s disease) can
be as high as 40% [5].
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Predictors of disease severity can be useful to the clin-
ician for anticipating complications. Factors predicting
mortality in severe leptospirosis as reported in various
studies worldwide have been reviewed by Rajapakse
et al. [6] under the categories of predisposition, insult,
response and organ dysfunction (similar to the PIRO
model used to predict mortality in severe sepsis). Al-
though there was insufficient data to develop a scoring
system for mortality prediction, it was noted in this re-
view that serum markers of acute inflammation (tumour
necrosis factor-α, interleukin-1, interleukin-6) have not
been adequately assessed as prognostic markers. These
pro-inflammatory cytokines lead to an increase in the
activity of inducible nitric oxide synthatase (iNOS) to
synthesize nitric oxide (NO) which is toxic to the bacter-
ium. The role of iNOS and NO production in inflamma-
tion has not been clearly determined in leptospirosis; in
fact its significance in severe sepsis [7] and other infec-
tions such as malaria [8-11] is subject to much debate
[12,13]. While its primary role is to combat infection,
NO levels have been shown to be elevated in severe
leptospirosis [14], leading to the postulate that high NO
levels may be involved in the pathogenesis of organ
dysfunction in leptospirosis. On the other hand, in-
creased iNOS activity may actually protect against organ
dysfunction.
NO is an extremely volatile compound that is difficult
to measure in serum. It is quickly converted to nitrite
(NO2
ˉ) and nitrate (NO3
ˉ) [15]. It is estimated that more
than 95% of nitrite in whole blood gets converted to ni-
trate within one hour [16]. Thus, the total blood levels
of nitrite and nitrate (NOx) could be considered to be a
surrogate marker of serum NO levels. NOx levels in
blood are affected by the amount of ingested nitrates; to
control for this, measurements should ideally be made
after an overnight fast [17]. Furthermore, NOx is ex-
creted renally, thus NOx clearance is reduced in the
presence of renal impairment [18]. To correct for this,
the use of the ratio of serum NOx/creatinine has been
suggested to be a more accurate marker of iNOS activity
than crude NOx levels, and was used in the study by
Anstey et al. [17] to correct NOx levels for renal func-
tion in patients with malaria. Although other factors
could influence creatinine levels, and therefore this cor-
rection factor too, creatinine levels are the standard
index used for assessment of renal dysfunction in acute
kidney injury [19]. Therefore the formula NOx/creatin-
ine is currently the only practical formula available to
correct NOx levels for renal function.
We previously demonstrated through a preliminary
study that serum nitrite levels are elevated in patients
with acute leptospirosis compared to healthy controls
[20]. However, the sample size was inadequate to deter-
mine a correlation with disease severity. The aim of this
study was to determine the relationship between NOx
(i.e., total nitrite and nitrate) levels in the blood (as a
marker of iNOS activity) and disease severity in lepto-
spirosis. If such a correlation exists, NOx could poten-
tially be useful as a prognostic marker.
Methods
Objectives
The objectives of our study were to a) determine serum
NOx (nitrate and nitrite) levels in patients with con-
firmed leptospirosis, b) compare serum NOx levels in
leptospirosis patients with mild and severe disease,
healthy controls and non-leptospirosis fever patients
(NLFs), and c) seek a correlation between serum NOx
levels and disease severity after correcting for impaired
renal clearance.
Participants
Patients suspected to have leptospirosis were selected
from the National Hospital of Sri Lanka (NHSL). The
NHSL is the premier tertiary care center in Sri Lanka,
with a bed strength of over 3600. It is one of the few
state sector centers with facilities for haemodialysis in
the country, and most patients with acute kidney injury
are transferred to NHSL for further management. It is
also the major hospital that covers the heavily populated
Western Province which is an endemic area for lepto-
spirosis [21]. The annual incidence of leptospirosis in
the Western Province for the year 2011 was 22 per
100,000 population.
All patients with a febrile illness who were clinically
suspected of having leptospirosis admitted to medical
wards in NHSL during a two-month period from 23rd
June to 27th August 2010 were included in to the study,
after obtaining informed consent. The clinical criteria to
define a probable case of leptospirosis were adopted
from the World Health Organization (WHO) surveil-
lance criteria [22]. Microscopic Agglutination Titre
(MAT) is the most widely used confirmatory test for
leptospirosis, although the duration that MAT remains
positive after infection is not clearly known [23]. None-
theless a MAT titre of > 400 is generally considered to
indicate acute infection even in areas of high endemicity,
in the setting of a clinical diagnosis of leptospirosis.
Based on MAT results, patients were retrospectively cat-
egorized as confirmed leptospirosis (MAT titre≥400,
MAT equivocal (MAT titre 100 and 200), and non-
leptospirosis fever (MAT negative). Healthy volunteers
(MAT negative) were selected as controls.
Serial haematological and serum biochemical mea-
surements of patients were made during the illness,
and included leukocyte and platelet counts, blood
culture, erythrocyte sedimentation rate (ESR), serum
potassium, serum sodium, aspartate aminotransferase,
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alanine aminotransferase, creatinine, blood urea and
indirect, direct and total bilirubin levels.
Patients with severe leptospirosis were defined as
those presenting with acute fever and clinical symptoms
compatible with leptospirosis (confirmed serologically
by a positive MAT result) with two or more of the
following criteria: jaundice (bilirubin> 51.3 μmol/l), oliguria
(urine output < 400 ml/day), serum creatinine> 133 μmol/l
or blood urea > 25.5 mmol/l [14], or the presence of acute
organ dysfunction.
Determination of serum NOX levels
Serum NOx levels were determined in all patients who
were recruited in to the study. NOx levels were mea-
sured in blood obtained early morning. Total NOx levels
were used as a surrogate marker for serum nitric oxide
levels [24].
The blood samples collected were centrifuged, and
separated sera were stored at −20°C. During analysis, the
serum samples were first thawed, then deproteinized by
adding zinc sulfate. Deproteinization is a necessary step
in the measurement of serum nitrite concentrations
[25]. Ten microlitres of 1.5 g/mL zinc sulphate solution
was added to 1mL of serum, vortexed for 1 minute, and
centrifuged at 10,000 g for 10 minutes at room
temperature (RT=25°C, i.e., the controlled temperature
in the laboratory). The supernatant was pipetted out and
centrifuged again at 10,000 g for 10 minutes. The clear
serum (100 μL) was applied in duplicate to a 96-well
ELISA plate, 100 μL of vanadium (III) chloride (8 mg/
mL) was added to each well (for reduction of nitrate to
nitrite) followed by the addition of 100 μL of Griess
reagent (equal mixture of 1% sulphanilamide in 5%
phosphoric acid and 0.1% N-(1-naphthyl) ethylenedi-
amine hydrochloride in distilled water). The plates were
incubated for 30 minutes at RT and the optical density
was measured at 540 nm using the ELISA reader
(Bio-Tek Instruments INC, USA). A two-fold dilution
series (0.193 - 100 μM) of NaNO2 was prepared from
100 μM NaNO2 solution using distilled water. Each
dilution (100 μL) was mixed with an equal volume of
Griess reagent, and the optical density (OD) was mea-
sured at 540 nm. A standard curve was plotted against
optical density and NaNO2 concentration. Intra-assay
coefficient of variability (CV) was 6.55% and inter-assay
CV was 8.62%, which indicated good precision and
repeatability.
Ethics
Ethics approval was obtained from the Ethics Review
Committee of the Faculty of Medicine, University of
Colombo and the Ethics Review Committee of the
NHSL. Informed written consent was obtained from
all patients and healthy controls prior to recruitment
to the study.
Statistical methods
Statistical analysis was performed using SPSSW version
17.0. Results were expressed as mean ± SD. Data were
analyzed by applying a one-way ANOVA with the
Bonferonni/Dunn post-hoc correction for multiple com-
parisons. Multivariate regression analysis was performed
to determine the relationship between NOx and other
biochemical markers of severity. Statistical significance
was defined as p < 0.05.
Results
Patient categorization
On the basis of clinical features, 85 patients were
recruited to the study with probable leptospirosis. Of
these, 40 were confirmed as leptospirosis with MAT
(titre of ≥400). There were also 27 patients who had
equivocal MAT titers and 18 with non-leptospirosis
fever (MAT negative). Twenty three MAT negative
healthy individuals were also recruited as controls. The
mean ± SD of the duration between onset of symptoms
and obtaining serum samples in the confirmed leptospir-
osis patients was 10.6 ± 3.9 days. The baseline character-
istics of these groups are shown in Table 1.
Of the 40 patients with confirmed leptospirosis, 26
were categorized as having severe disease according to
the criteria mentioned above. One patient with severe
disease died and all others survived. The laboratory
investigations for each category of patients and for non-
leptospirosis fever patients are summarized in Table 2.
Comparison of uncorrected serum NOX levels
We first compared NOx levels of confirmed leptospirosis
patients (mild and severe) MAT equivocal patients, NLF
patients, and healthy controls (Table 3 and Figure 1,
Table 4). Significantly higher NOx levels were observed
in confirmed leptospirosis patients when compared
against healthy controls, MAT equivocal patients and
non-leptospirosis fever patients (p<0.001). NOx concen-
trations in patients with severe leptospirosis were also
significantly higher than in those with mild leptospirosis
(p=0.003). There was no significant difference in values
between MAT equivalent patients and non-leptospirosis
fever patients. Notably, many of these differences were
not observed when the serum nitrite levels alone were
considered.
Comparison of NOx levels corrected for impaired renal
function
In order to correct for renal impairment, we calculated
the serum NOx/creatinine ratio in each of the groups.
The comparisons of these groups are shown in Table 5
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and Figure 2 (also Table 6). Corrected NOx were lower
among patients confirmed to have leptospirosis com-
pared to healthy controls, although the difference was
marginal. There was no significant difference seen in
corrected NOx levels among confirmed leptospirosis pa-
tients, MAT equivocal patients and NLFs.
The most significant finding was that corrected NOx
levels were markedly lower among patients with severe
leptospirosis compared with both mild leptospirosis and
MAT-equivocal patients. On the other hand, no differ-
ence was seen in corrected NOx levels in severe lepto-
spirosis patients, healthy controls and NLF patients.
Corrected NOx levels were significantly lower among
healthy controls compared with mild leptospirosis pa-
tients and MAT equivocal patients, but no significant
difference was shown between healthy controls and
NLFs.
Discussion
Elevation of serum NOx levels during acute infections
such as dengue, malaria and leptospirosis has been
shown in previous studies, however the main criticism
of these studies has been the lack of correction of NOx
concentrations for renal function. As mentioned above,
NOx is excreted predominantly by the kidneys, and NOx
levels have been shown to be elevated in the presence of
renal impairment.
We demonstrated that crude NOx levels are signifi-
cantly elevated in leptospirosis, with higher levels correl-
ating with severity of the illness. However, once NOx
levels were corrected for renal function, they were sig-
nificantly lower in severe leptospirosis. If NOx levels re-
flect iNOS activity, this finding suggests that iNOS
activity is diminished in patients developing severe dis-
ease. Furthermore, the results suggest that iNOS activity
is similar in severe leptospirosis and healthy controls
despite the heavy inflammatory response in the former
group. We postulate that this indicates that a blunted
iNOS response is seen in severe leptospirosis; whether
this is the result of the inflammatory response that oc-
curs, or whether a diminished iNOS response plays a
role in the genesis of severe leptospirosis and organ dys-
function remains to be elucidated. Conversely, it is pos-
sible that higher levels of NOx are protective against
organ dysfunction. Admittedly, the relationship between
iNOS activity and inflammation is extremely complex.
Nonetheless, similar patterns have been seen in mal-
aria. Al Yaman et al. [10] described an association be-
tween high levels of NOx levels and coma in children
with cerebral malaria. Similarly Kremsner et al. [9]
showed that higher levels of plasma NO were seen in
severe malaria; however they also demonstrated that
higher levels of NO was associated with accelerated
recovery. The criticism of both these studies was that
crude NO levels were considered, and no correction was
made for deranged renal function (serum creatinine
levels in the patients were not provided), and that the el-
evated NO levels could simply be related to reduced ex-
cretion of NO due to impairment of renal function [13].
In fact, Anstey et al. [11] demonstrated that when NOx
Table 1 Comparison of age and gender among the study groups
Confirmed leptospirosis patients MAT equivocal patients Non-leptospirosis fever controls
Number of patients 40 27 18
MAT titre ≥ 400 100-200 0
Mean age ± SD (years) 39.7 ± 14.6 38.4 ± 15.2 37.8 ± 13.8
Gender (Male:Female) 19 : 1 26 : 1 8 : 1
Table 2 Laboratory parameters of mild and sever leptospirosis patients, MAT equivocal patients and non-leptospirosis
fever controls (univariate analysis)








WBC-highest (cells/mm3) 15461 ± 9625 11418 ± 5071 12170 ± 3637 11650 ± 2703
Platelets-lowest (cells/mm3) 114714 ± 91166 142154 ± 72178 NA NA
ESR-highest (mm/hour) 59.8 ± 42.7 45.6 ± 41.1 47.6 ± 40.8 45.3 ± 23.9
Bilirubin-total (μmol/l) 159.0 ± 140.2* 49.7 ± 37.2 52.1 ± 40.6 61.29 ± 69.5
AST (U/L) 138.6 ± 90.0 97.5 ± 75.3 140.9 ± 141.7 89.8 ± 68.7
ALT (U/L) 105.4 ± 58.0 94.6 ± 63.3 89.7 ± 59.9 62.4 ± 27.7
Blood urea (mmol/l) 16.0 ± 8.3* 5.7 ± 5.4 6.7 ± 3.9 6.7 ± 4.6
Serum creatinine (μmol/l) 520.4 ± 200.4* 113.3 ± 15.6 153.6 ± 142.9 140.1 ± 82.1
† mean ± SD; NA – not available; *differed at a statistically significant level (p<0.001) from patients with mild disease and MAT equivocal patients.
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Table 3 ANOVA post-hoc comparison using Bonferonni correction comparing uncorrected NOx in the different groups
(I) Category (J) Category Mean difference (I-J) Std. error Sig.
NLF MAT eq -.509167 2.661898 1.000
Mild lepto −7.622690 3.117296 .162
Severe lepto −18.547372* 2.682296 .000
Controls 7.444000 2.727634 .075
MAT equivocal NLF .509167 2.661898 1.000
Mild lepto −7.113524 2.881040 .152
Severe lepto −18.038205* 2.403658 .000
Controls 7.953167* 2.454149 .016
Mild leptospirosis NLF 7.622690 3.117296 .162
MAT eq 7.113524 2.881040 .152
Severe lepto −10.924681* 2.899897 .003
Controls 15.066690* 2.941883 .000
Severe leptospirosis NLF 18.547372* 2.682296 .000
MAT eq 18.038205* 2.403658 .000
Mild lepto 10.924681* 2.899897 .003
Controls 25.991372* 2.476259 .000
Healthy Controls NLF −7.444000 2.727634 .075
MAT eq −7.953167* 2.454149 .016
Mild lepto −15.066690* 2.941883 .000
Severe lepto −25.991372* 2.476259 .000
NLF: Non-leptospirosis fever, MAT eq: MAT equivocal patients, lepto: leptospirosis. Sig: significance. * denotes statistically significant differences.
Figure 1 Serum NOx levels in different patient groups and healthy controls. NLF: Non-leptospirosis fever; MAT Eq: MAT equivocal patients.
lepto: leptospirosis.
Kalugalage et al. BMC Infectious Diseases 2013, 13:206 Page 5 of 8
http://www.biomedcentral.com/1471-2334/13/206
levels were corrected for renal function, using the ratio
NOx/Creatinine, NOx levels showed an inverse relation-
ship with the severity of malaria. Corrected NOx levels
were lowest in patients with severe disease, while higher
levels were seen in controls as well as those with asymp-
tomatic disease, suggesting that high NOx levels may
protect against severe malaria. Furthermore, in a mouse
model, Gramaglia et al. [26] demonstrated that low NO
bioavailability contributes to the genesis of experimental
cerebral malaria.
Although many confounding factors could be present,
the finding that corrected NOx levels are low in clinically
severe leptospirosis is itself of significance. Whether
NOx levels are low in severe leptospirosis as a result of
endothelial dysfunction resulting from severe disease, or
whether individuals in whom iNOS activity does not in-
crease in response to infection are more likely to develop
severe disease remains unclear. Another possibility is
that iNOS activity is normal, but the NO produced is
rapidly removed by other molecules such as reactive
oxygen species and haemoglobin. The measurement of
serial NOx levels and correlating these with the onset of
organ dysfunction in patients with leptospirosis and in
experimental models is likely to provide further insight
into this issue.
The finding that corrected NOx levels in NLFs were
similar to those seen in severe leptospirosis is interest-
ing. NLFs presumably represent a heterogenous group,
and a significant number in this group had renal
dysfunction. Whether this suggests a decrease in NOx
levels in infections which result in organ dysfunction is
difficult to determine from this study. Clinical features
similar to those of severe leptospirosis occur in many
other infections, such as dengue, hanta-virus and acute
hepatitis; some of the patients in the NLF and MAT
equivocal groups did present with clinical features simi-
lar to severe leptospirosis; however numbers were too
small for any realistic comparisons of NO levels in these
subgroups to be possible.
The Griess reaction explained in the methodology is
specific for nitrite levels in blood. Therefore in order to
measure the nitrates, they had to be converted to
nitrites. This conversion can be achieved with either a
chemical or an enzymatic reduction and we opted
for the chemical measure by treating the sera with
Vanadium(III) chloride [7,14]. The use of Vanadium (III)
chloride offers a low cost method compared to the
enzymatic reduction and therefore the modified Griess
assay is an inexpensive, simple, rapid, accurate and a
sensitive method for measurement of NOX levels, better
suited method for resource limited settings in develop-
ing countries.
Limitations
One of the limitations of this study is the confounding
factors that can affect serum NOX levels such as age and
diet [27]. However, the mean ages of the subjects in the
different groups were comparable, and dietary influence
was minimized by collecting samples in the early morn-
ings prior to the intake of food. It was also possible that
patients with severe disease had a lower dietary contri-
bution of nitrites. This is very difficult to quantify in a
clinical study, and no standard methods for quantifica-
tion exist. However in our study, we compared the
incidence and severity of symptoms such as nausea,
vomiting and loss of appetite, and there was no differ-
ence in the incidence of these symptoms in severe
Table 4 NOX values in the different categories
Category N Mean SD SEM
Confirmed leptospirosis 40 28.247 11.425 1.806
Severe leptospirosis 26 32.071 11.773 2.309
Mild leptospirosis 14 21.146 6.441 1.722
MAT equivocal 27 14.032 7.579 1.459
Non-leptospirosis fever 18 13.523 11.581 2.730
Healthy controls 23 6.078 2.802 0.572
Table 5 ANOVA post-hoc comparison using Bonferonni
correction comparing NOx/creatinine in the different
groups
(I) Category (J) Category Mean difference (I-J) Std. error Sig.
NLF MAT eq -.026593 .020710 1.000
Mild Lepto -.087484* .024253 .005
Severe lepto .029598 .020869 1.000
Controls .019194 .021222 1.000
MAT eq NLF .026593 .020710 1.000
Mild Lepto -.060892 .022415 .077
Severe lepto .056191* .018701 .033
Controls .045787 .019094 .183
Mild lepto NLF .087484* .024253 .005
MAT eq .060892 .022415 .077
Severe lepto .117082* .022562 .000
Controls .106679* .022889 .000
Severe lepto NLF -.029598 .020869 1.000
MAT eq -.056191* .018701 .033
Mild Lepto -.117082* .022562 .000
Controls -.010404 .019266 1.000
Controls NLF -.019194 .021222 1.000
MAT eq -.045787 .019094 .183
Mild Lepto -.106679* .022889 .000
Severe lepto .010404 .019266 1.000
NLF: Non-leptospirosis fever, MAT eq: MAT equivocal patients, lepto:
leptospirosis, Sig: significance. * denotes statistically significant differences.
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disease compared with non-severe disease. All patients,
even the sickest, were able to eat and drink. There was a
gender bias in the sample with more males than females.
However, this is a well established epidemiological fact
in leptospirosis in Sri Lanka, as it is the males who
engage more in outdoor activities such as farming which
is a major occupational risk factor for leptospirosis [21].
Of the serological tests to diagnose leptospirosis, MAT
is the preferred method, and it is also the test
recommended by the epidemiology unit of the Ministry
of Health in Sri Lanka [21]. However, MAT serology
may be insensitive in early acute-phase specimens [28].
Moreover, patients with fulminant leptospirosis may die
before seroconversion occurs. A four-fold rise in MAT
titer would have helped to differentiate patients with
true leptospirosis in the MAT equivocal group [22,29].
However, many patients did not return for follow up
visits after discharge and we had to restrict the leptospir-
osis confirmed group to those with high MAT titers
≥400. We did not obtain serial NOx measurements in
patients (due to logistical difficulties and limited
resources) which would have enabled us to predict the
earliest point at which NOX levels would start to differ
in those with severe disease, thus establishing the
approximate earliest point it would be useful as a
predictive marker. Based on the results of this initial
study a larger multi-centre study was designed by us,
and is currently in progress.
Conclusions
This study shows that crude serum NOX levels were
significantly elevated in Sri Lankan patients with
leptospirosis compared to healthy controls and non-
leptospirosis fever patients; however once NOx levels
were corrected for serum creatinine, the relationship be-
tween NOx levels and disease severity was shown to be
strikingly different. Corrected NOx levels were signifi-
cantly suppressed in patients with severe leptospirosis.
Thus, NOx levels in patients with leptospirosis may be
useful to predict severe disease, i.e., the presence of low
NOx levels (after correction for renal function) in lepto-
spirosis may predict the development or organ dysfunc-
tion. We also demonstrated that chemical conversion of
nitrates to nitrite with Vanadium (III) chloride and
Figure 2 Corrected NOx (NOx/creatinine) in different patient groups and healthy controls. NLF: Non-leptospirosis fever; MAT Eq: MAT
equivocal patients. lepto: leptospirosis.
Table 6 NOx/creatinine levels in the different study
groups
Category N Mean SD SEM
Confirmed leptospirosis 40 0.113 0.074 0.012
Severe leptospirosis 26 0.072 0.042 0.008
Mild leptospirosis 14 0.189 0.058 0.015
MAT equivocal 27 0.128 0.096 0.018
Non-leptospirosis fever 18 0.101 0.085 0.020
Healthy controls 23 0.082 0.038 0.008
Kalugalage et al. BMC Infectious Diseases 2013, 13:206 Page 7 of 8
http://www.biomedcentral.com/1471-2334/13/206
measuring of NOX levels (modified Griess reaction) is a
relatively cheap assay technique that can be employed in
resource limited settings.
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